Sculpta Bio
- Biotech or pharma, therapeutic R&D
Sculpta is a Stanford spinout pioneering a new approach to RNA therapeutics for neurodegenerative and psychiatric diseases. Unlike conventional gene therapies that simply alter gene expression levels, Sculpta rewires alternative RNA splicing to precisely reshape the structure and function of disease-causing proteins in the brain—an approach we call Protein Sculpting TM. This approach enables us to make precision changes to specific protein domains to alter enzyme kinetics, protein localization, and individual binding partners. Our platform integrates innovations enabling RNA splicing-sensitive transcriptomics from 100K+ single cells or individual samples, and an AI-driven RNA splicing target detection platform to identify and validate novel targets inaccessible with traditional methods. We are led by former Stanford faculty and board certified physician scientist, Neal Amin, MD, PhD, with publications in top tier journals including Nature, Cell, Science, etc.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}